8-K: IO Biotech Secures Up to $57.5 Million in Debt Financing from European Investment Bank

IO Biotech has secured a debt financing agreement with the European Investment Bank for up to $57.5 million to advance its therapeutic cancer vaccine programs.

Summary

• IO Biotech has entered into a debt financing agreement with the European Investment Bank (EIB) for up to 57.5 million euros.
• The facility includes three committed tranches totaling 37.5 million euros, and one uncommitted accordion tranche of 20 million euros.
• The first two tranches are expected to be available in the first quarter of 2025.
• The funds are intended to support the development and pre-commercialization of IO102-IO103 and other therapeutic cancer vaccine candidates.
• The company expects the committed tranches to extend its cash runway into the second quarter of 2026.
• Each committed tranche will become available if the company satisfies certain conditions precedent.
• Tranche C conditions include raising an additional $50 million in cash and submitting a marketing authorization application for IO102-IO103 in the U.S. or the EU.
• Each tranche has a maturity of 6 years from its disbursement, with capitalized interest and payment deferred to maturity.
• The company will issue warrants to the EIB to purchase shares of the company's common stock in connection with the disbursement of each tranche.

Sentiment

Score: 7

Explanation: The document is positive overall, as it secures significant funding for the company. However, the financing is debt-based and includes conditions, which introduces some risk. The sentiment is therefore moderately positive.

Positives

• The debt facility is unsecured and has no minimum cash covenants.
• The financing is expected to support the continued development and pre-commercialization of IO102-IO103 and other therapeutic cancer vaccine candidates.
• The loan is structured with capitalized interest and payment deferred to maturity of each tranche.

Negatives

• The availability of the committed tranches is subject to the company satisfying certain conditions precedent.
• The uncommitted accordion tranche of 20 million euros is subject to the EIB's discretion and approval.

Risks

• The company may not be able to satisfy the conditions precedent for the disbursement of the committed tranches.
• The company may not be able to raise the additional $50 million in cash required for Tranche C.
• The company may not be able to obtain marketing authorization for IO102-IO103 in the U.S. or the EU.
• The company may not be able to achieve the clinical trial milestones required for the disbursement of Tranche B.

Future Outlook

The company expects the committed tranches to extend its cash runway into the second quarter of 2026 and to advance its therapeutic cancer vaccine programs, including a potential BLA submission for IO102-IO103 in 2025.

Management Comments

• Amy Sullivan, Chief Financial Officer of IO Biotech, commented, The support from the EIB, which is provided on favorable terms, will help fund the continued development and pre-commercialization of IO102-IO103 and other therapeutic cancer vaccine candidates generated from our T-Win platform.
• We expect that the capital drawn from the three committed tranches of the EIB debt facility will extend our cash runway into the second quarter of 2026.

Industry Context

This announcement highlights the EIB's commitment to supporting biotech companies with expertise in immuno-oncology, a rapidly growing field in cancer therapeutics. The financing will enable IO Biotech to further develop its novel cancer vaccine platform and potentially bring new treatment options to patients.

Comparison to Industry Standards

• The financing structure, with a combination of committed and uncommitted tranches, is a common approach in biotech debt financing, allowing for flexibility based on the company's progress and milestones.
• The 8% fixed interest rate is within the typical range for venture debt financing in the biotech sector, reflecting the risk profile of the company and the stage of its development.
• The requirement to issue warrants to the EIB is a standard practice in venture debt deals, providing the lender with potential upside in the company's future success.
• The 6-year maturity and capitalized interest structure are favorable for a clinical-stage biotech company, allowing it to focus on R&D without immediate cash flow pressures.
• The requirement to raise an additional $50 million in cash for Tranche C is a common milestone-based condition in biotech financing, incentivizing the company to achieve key development goals.

Stakeholder Impact

• Shareholders: The financing is expected to extend the company's cash runway, which is positive for shareholders. However, the issuance of warrants may dilute existing shareholders.
• Employees: The financing will support the continued development of the company's pipeline, which is positive for employees.
• Customers: The financing will support the development of new cancer treatments, which is positive for patients.
• Suppliers: The financing may lead to increased spending with suppliers.
• Creditors: The EIB is a new creditor of the company.

Next Steps

• The company expects to receive the first two tranches of the loan facility in the first quarter of 2025.
• The company will need to satisfy certain conditions precedent to access the committed tranches.
• The company will need to raise an additional $50 million in cash to access Tranche C.
• The company will need to submit a marketing authorization application for IO102-IO103 in the U.S. or the EU to access Tranche C.

Key Dates

Keywords

IO Biotech, European Investment Bank, debt financing, cancer vaccines, IO102-IO103, clinical trials, immunotherapy, warrants, cash runway, EIB